Number of responders to polyribosylribitol phosphate (PRP) antigen Post-dose 3 (12 to 13 Months) [clinicaltrials_resource:928e07d5ff18f906127cfca9f40d3914]
V419 + Rotavirus vaccine + Prevenar 13
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]
Number of responders to polyribosylribitol phosphate (PRP) antigen Post-dose 3 (12 to 13 Months) [clinicaltrials_resource:928e07d5ff18f906127cfca9f40d3914]
V419 + Rotavirus vaccine + Prevenar 13
Bio2RDF identifier
928e07d5ff18f906127cfca9f40d3914
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:928e07d5ff18f906127cfca9f40d3914
measure [clinicaltrials_vocabulary:measure]
Number of responders to polyribosylribitol phosphate (PRP) antigen
time frame [clinicaltrials_vocabulary:time-frame]
Post-dose 3 (12 to 13 Months)
description
V419 + Rotavirus vaccine + Prevenar 13
identifier
clinicaltrials_resource:928e07d5ff18f906127cfca9f40d3914
title
Number of responders to polyri ...... Post-dose 3 (12 to 13 Months)
@en
type
label
Number of responders to polyri ...... e07d5ff18f906127cfca9f40d3914]
@en